期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替莫唑胺在垂体肿瘤治疗中的应用 被引量：3

原文传递
导出
摘要 替莫唑胺（temozolomide，TMZ）是一种口服二代烷化剂，具有广谱抗肿瘤活性。TMZ除作为恶性胶质瘤一线药物外，对神经内分泌肿瘤也有效，在治疗侵袭性垂体腺瘤与垂体腺癌中获得良好效果。本文将TMZ在垂体肿瘤中的应用进展做一综述。
作者 王文达 幸兵
机构地区 中国医学科学院北京协和医学院北京协和医院神经外科
出处 《中华神经外科杂志》 CSCD 北大核心 2014年第5期533-535,共3页 Chinese Journal of Neurosurgery
关键词 垂体肿瘤 替莫唑胺 应用 治疗 广谱抗肿瘤活性 神经内分泌肿瘤 侵袭性垂体腺瘤 恶性胶质瘤
分类号 R736.4 [医药卫生—肿瘤]
  • 相关文献

参考文献29

  • 1Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as mono- therapy is effective in treatment of advanced malignant neuroendocrine tumors [ J ] . Clin Cancer Res, 2007, 13: 2986-2991.
  • 2Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide : A review [ J ]. Cancer, 2011,117 : 454-462.
  • 3McCormack AI, McDonald KL, Gill A J, et al. Low 06-methy- lguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours[ J]. Clin Endocrinol (Oxf) ,2009,71:226-233.
  • 4Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-seereting pituitary neoplasm: morphological findings[ J]. Hum Pathol,2007 ,38 :185-189.
  • 5Neff LM, Weil M, Cole A, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists [ J ]. Pituitary ,2007,10:81 -86.
  • 6Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy [ J ] . Eur J Endocrinol, 2009, 161 : 631-637.
  • 7Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide trea- tment for aggressive pituitary tumors: correlation of clinical outcome with O ( 6 ) -methylguanine methyltransferase ( MGMT ) promoter methylation and expression [ J ]. J Clin Endocrinol Metab ,2010,95 : E280-E290.
  • 8Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temo- zolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases[ J]. Eur J Endocrinol, 2010, 163:843-851.
  • 9Whitelaw BC, Dworakowska D, Thomast NW, et al. Temozolomide in the management of dopamine agonist resistant prolactinomas [ J]. Clin Endocrinol (Oxf) ,2012,76:877-886.
  • 10Mohammend S, Kovacs K, Mason W, et al. Use of temozolomide in aggressive pituitary tumors : case report [ J ]. Neurosurgery,2009, 64 : E773-774.

二级参考文献8

  • 1Aghi MK. Management of recurrent and refractory Cushing dise- ase. Nat Clin Pract Endocrinol Metab,2008 ,4 :560-568.
  • 2Syro LV,Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 2011, 117 : 454-462.
  • 3Fadul CE,Kominsky AI,, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two eases. J Neurosurg ,2006,105:621-626.
  • 4McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylg- uanine-DNA methyltransferase(MGMT) expression and response to temozolomide in aggressive pituitary turnouts. Clin Endocrinol (Oxf) ,2009,71:226-233.
  • 5Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT imm-unoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol,2008,115:261-262.
  • 6Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas:a French muhicenter experience. J Clin Endocrinol Metab, 2010, 95: 4592-4599.
  • 7Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide trea- tment for aggressive pituitary tumors: correlation of clinical outcome with O ( 6 ) -methylguanine methyltransferase ( MGMT ) promoter methylation and expression. J Clin Endocrinol Metab, 2010,95 : E280-E290.
  • 8Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary, 2010. [ Epub ahead of print ].

共引文献7

同被引文献24

引证文献3

二级引证文献9

中华神经外科杂志
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部